Naashika Quarcoo

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

Thomas Voit, Haluk Topaloğlu, Volker Straub et al. · The Lancet Neurology · 2014 · 295 citations

Medicine, Pharmacology, Pharmacotherapy +5

Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases

Gianmario Candore, Kristina Juhlin, Katrin Manlik et al. · Drug Safety · 2015 · 145 citations

Pharmacy, Biostatistics, Statistical Computing +13

Good Signal Detection Practices: Evidence from IMI PROTECT

A Wisniewski, Andrew Bate, Cédric Bousquet et al. · Drug Safety · 2016 · 144 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacology +17

Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial

Kevin M. Flanigan, Thomas Voït, Xiomara Q. Rosales et al. · Neuromuscular Disorders · 2013 · 70 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +14

Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases

Suzie Seabroke, Gianmario Candore, Kristina Juhlin et al. · Drug Safety · 2016 · 56 citations

Public Health, Biostatistics, Databases +10